View Author
Beurden, V. van
( V. van Beurden)
patient topotecan docetaxel r 101933 study administration b.i.d cancer pharmacokinetic schedule course level plasma 100 mg /m dose level phase cycle toxicity treatment table concentration p-glycoprotein diarrhea 21 days effect infusion decrease inhibitor range grade tumor oncol lactone paclitaxel percentage decrease topoisomerase 21- analysis 5 administration side effect dose levels anticancer resistance percentage 1996. rotterdam cancer institute combination 200 mg b.i.d parameter sample 10 days value research topotecan lactone myelotoxicity multidrug resistance duration correlation treatment courses 21- day 21- day schedule camptothecin 5 days intrapatient variation phase i 5- day schedule 21- day administration topoisomerase i inhibitor exposure blood granulocytopenia number variation leukocyte agent rotterdam anticancer drugs interaction verweij cycle 2
2 Most Recent Publications
|
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
(Article)
Zuylen, L. van Sparreboom, A. Gaast, A. van der Burg, M.E.L. van der Beurden, V. van Bol, C.J. Woestenborghs, R. Palmer, P.A. Verweij, J. |
2000-01-01
|
|
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
(Article)
Gerrits, C.J.H. Hudson, I. Loos, W.J. Beurden, V. van Verweij, J. Von Hoff, D.D. Schellens, J.H. Burris, H. Eckardt, J.R. Planting, A.S.Th. Burg, M.E.L. van der Rodriguez, G.I. |
1999-01-01
|
